​

West Pharmaceutical Services (WST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WST Stock Forecast

West Pharmaceutical Services (WST) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $345.20, with a high of $390.00 and a low of $311.00. This represents a 21.77% increase from the last price of $283.49.

$250 $280 $310 $340 $370 $400 High: $390 Avg: $345.2 Low: $311 Last Closed Price: $283.49

WST Stock Rating

West Pharmaceutical Services stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (71.43%), 3 Hold (21.43%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 3 10 Strong Sell Sell Hold Buy Strong Buy

WST Price Target Upside V Benchmarks

TypeNameUpside
StockWest Pharmaceutical Services21.77%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks22.33%

Price Target Trends

1M3M12M
# Anlaysts679
Avg Price Target$340.00$335.86$332.11
Last Closing Price$283.49$283.49$283.49
Upside/Downside19.93%18.47%17.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 252102--14
Sep, 25292--13
Aug, 25292--13
Jul, 25392--14
Jun, 252101--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Barclays$325.00$293.6210.69%14.64%
Oct 24, 2025Dan LeonardUBS$355.00$307.2515.54%25.22%
Oct 24, 2025Justin BowersDeutsche Bank$345.00$304.7413.21%21.70%
Oct 23, 2025Daniel MarkowitzEvercore ISI$390.00$309.2826.10%37.57%
Oct 07, 2025Evercore ISI$350.00$268.0730.56%23.46%
Oct 02, 2025Barclays$275.00$271.421.32%-2.99%
Sep 15, 2025Jamie ClarkRedburn Partners$311.00$257.5320.76%9.70%
Jun 24, 2025Luke SergottBarclays$245.00$222.6810.02%-13.58%
Nov 19, 2024David WindleyJefferies$393.00$287.8536.53%38.63%
Feb 07, 2024David WindleyJefferies$536.00$413.0029.78%89.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2025Cowen & Co.Buyinitialise
Oct 24, 2025UBSBuyBuyhold
Oct 24, 2025Deutsche BankBuyBuyhold
Oct 23, 2025Evercore ISIOutperformOutperformhold
May 22, 2025CitigroupBuyBuyhold
Jan 08, 2025CitigroupBuyinitialise
Nov 19, 2024JefferiesBuyBuyhold
Feb 15, 2024William BlairOutperformOutperformhold
Feb 07, 2024JefferiesBuyupgrade
Jun 16, 2023Morgan StanleyBuyupgrade

Financial Forecast

EPS Forecast

$4 $5 $6 $7 $8 $9 $10 $11 $12 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.68$8.90$7.88$7.99$6.75----
Avg Forecast$4.54$8.49$8.17$8.01$6.63$7.45$8.77$9.98$11.10
High Forecast$4.61$8.62$8.27$8.10$6.67$7.67$9.11$10.17$11.31
Low Forecast$4.49$8.40$8.10$7.96$6.55$7.30$8.29$9.82$10.92
Surprise %3.08%4.83%-3.55%-0.25%1.81%----

Revenue Forecast

$2B $2B $3B $3B $4B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.15B$2.83B$2.89B$2.95B$2.89B----
Avg Forecast$2.10B$2.81B$2.84B$2.96B$2.88B$3.04B$3.31B$3.50B$3.71B
High Forecast$2.13B$2.84B$2.86B$3.00B$2.89B$3.06B$3.31B$3.52B$3.77B
Low Forecast$2.08B$2.79B$2.82B$2.92B$2.85B$3.03B$3.31B$3.48B$3.67B
Surprise %2.19%0.73%1.82%-0.26%0.29%----

Net Income Forecast

$200M $340M $480M $620M $760M $900M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$346.20M$661.80M$585.90M$593.40M$492.70M----
Avg Forecast$264.28M$503.69M$609.47M$593.40M$499.60M$563.43M$637.89M$749.00M$835.83M
High Forecast$317.13M$604.43M$731.37M$712.08M$502.29M$577.28M$685.83M$765.83M$851.78M
Low Forecast$211.42M$402.95M$487.58M$474.72M$493.31M$549.58M$623.92M$739.61M$822.61M
Surprise %31.00%31.39%-3.87%--1.38%----

WST Forecast FAQ

Is West Pharmaceutical Services stock a buy?

West Pharmaceutical Services stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that West Pharmaceutical Services is a favorable investment for most analysts.

What is West Pharmaceutical Services's price target?

West Pharmaceutical Services's price target, set by 14 Wall Street analysts, averages $345.2 over the next 12 months. The price target range spans from $311 at the low end to $390 at the high end, suggesting a potential 21.77% change from the previous closing price of $283.49.

How does West Pharmaceutical Services stock forecast compare to its benchmarks?

West Pharmaceutical Services's stock forecast shows a 21.77% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical instruments & supplies stocks industry (22.33%).

What is the breakdown of analyst ratings for West Pharmaceutical Services over the past three months?

  • October 2025: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 15.38% Strong Buy, 69.23% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 15.38% Strong Buy, 69.23% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.

What is West Pharmaceutical Services’s EPS forecast?

West Pharmaceutical Services's average annual EPS forecast for its fiscal year ending in December 2025 is $7.45, marking a 10.37% increase from the reported $6.75 in 2024. Estimates for the following years are $8.77 in 2026, $9.98 in 2027, and $11.1 in 2028.

What is West Pharmaceutical Services’s revenue forecast?

West Pharmaceutical Services's average annual revenue forecast for its fiscal year ending in December 2025 is $3.04B, reflecting a 5.04% increase from the reported $2.89B in 2024. The forecast for 2026 is $3.31B, followed by $3.5B for 2027, and $3.71B for 2028.

What is West Pharmaceutical Services’s net income forecast?

West Pharmaceutical Services's net income forecast for the fiscal year ending in December 2025 stands at $563.43M, representing an 14.36% increase from the reported $492.7M in 2024. Projections indicate $637.89M in 2026, $749M in 2027, and $835.83M in 2028.